Cargando…
Clinicopathological characteristics of patients with HER2-positive breast cancer and the efficacy of trastuzumab in the People’s Republic of China
OBJECTIVE: The aim of this study was to describe the clinical features and outcomes of Chinese patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. METHOD: The clinical data and survival statuses of 732 patients with operable HER2-positive breast cancer who were trea...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4846044/ https://www.ncbi.nlm.nih.gov/pubmed/27143924 http://dx.doi.org/10.2147/OTT.S97583 |
_version_ | 1782429025733443584 |
---|---|
author | Zhou, Ping Jiang, Yi-Zhou Hu, Xin Sun, Wei Liu, Yi-Rong Liu, Fang Luo, Rong-Cheng Shao, Zhi-Ming |
author_facet | Zhou, Ping Jiang, Yi-Zhou Hu, Xin Sun, Wei Liu, Yi-Rong Liu, Fang Luo, Rong-Cheng Shao, Zhi-Ming |
author_sort | Zhou, Ping |
collection | PubMed |
description | OBJECTIVE: The aim of this study was to describe the clinical features and outcomes of Chinese patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. METHOD: The clinical data and survival statuses of 732 patients with operable HER2-positive breast cancer who were treated at the Department of Breast Surgery of the Shanghai Cancer Center from January 1, 2007, to December 31, 2011, were collected. The patients were divided into two groups according to treatment with and without trastuzumab. Disease-free survival (DFS) and overall survival were calculated using the Kaplan–Meier method and log-rank test. The associations of the patient characteristics with prognosis were analyzed via Cox regression. RESULTS: A total of 732 women with HER2-positive breast cancer were included in this study, among whom 258 (35.2%) received trastuzumab. The median follow-up duration was 41 months. By the end of the follow-up period, 86 (12%) women experienced local recurrence or metastasis. Patients who received both anti-HER2 therapy and chemotherapy exhibited a longer DFS than those who received chemotherapy alone (P=0.001). Tumor size, lymph node status, and family history of breast cancer were associated with median DFS, and tumor size, lymph node status, clinical stage, age, and body mass index were associated with median overall survival. Patients who received both neoadjuvant chemotherapy and trastuzumab exhibited a higher rate of pathological complete remission. In the neoadjuvant group, the patients who received both anti-HER2 therapy and chemotherapy exhibited a longer DFS than those who received chemotherapy alone (P=0.049). CONCLUSION: Significant clinical features were observed in the Chinese patients with HER2-positive breast cancer. Furthermore, targeted anti-HER2 therapy may improve the prognosis of these patients. |
format | Online Article Text |
id | pubmed-4846044 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-48460442016-05-03 Clinicopathological characteristics of patients with HER2-positive breast cancer and the efficacy of trastuzumab in the People’s Republic of China Zhou, Ping Jiang, Yi-Zhou Hu, Xin Sun, Wei Liu, Yi-Rong Liu, Fang Luo, Rong-Cheng Shao, Zhi-Ming Onco Targets Ther Original Research OBJECTIVE: The aim of this study was to describe the clinical features and outcomes of Chinese patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. METHOD: The clinical data and survival statuses of 732 patients with operable HER2-positive breast cancer who were treated at the Department of Breast Surgery of the Shanghai Cancer Center from January 1, 2007, to December 31, 2011, were collected. The patients were divided into two groups according to treatment with and without trastuzumab. Disease-free survival (DFS) and overall survival were calculated using the Kaplan–Meier method and log-rank test. The associations of the patient characteristics with prognosis were analyzed via Cox regression. RESULTS: A total of 732 women with HER2-positive breast cancer were included in this study, among whom 258 (35.2%) received trastuzumab. The median follow-up duration was 41 months. By the end of the follow-up period, 86 (12%) women experienced local recurrence or metastasis. Patients who received both anti-HER2 therapy and chemotherapy exhibited a longer DFS than those who received chemotherapy alone (P=0.001). Tumor size, lymph node status, and family history of breast cancer were associated with median DFS, and tumor size, lymph node status, clinical stage, age, and body mass index were associated with median overall survival. Patients who received both neoadjuvant chemotherapy and trastuzumab exhibited a higher rate of pathological complete remission. In the neoadjuvant group, the patients who received both anti-HER2 therapy and chemotherapy exhibited a longer DFS than those who received chemotherapy alone (P=0.049). CONCLUSION: Significant clinical features were observed in the Chinese patients with HER2-positive breast cancer. Furthermore, targeted anti-HER2 therapy may improve the prognosis of these patients. Dove Medical Press 2016-04-18 /pmc/articles/PMC4846044/ /pubmed/27143924 http://dx.doi.org/10.2147/OTT.S97583 Text en © 2016 Zhou et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Zhou, Ping Jiang, Yi-Zhou Hu, Xin Sun, Wei Liu, Yi-Rong Liu, Fang Luo, Rong-Cheng Shao, Zhi-Ming Clinicopathological characteristics of patients with HER2-positive breast cancer and the efficacy of trastuzumab in the People’s Republic of China |
title | Clinicopathological characteristics of patients with HER2-positive breast cancer and the efficacy of trastuzumab in the People’s Republic of China |
title_full | Clinicopathological characteristics of patients with HER2-positive breast cancer and the efficacy of trastuzumab in the People’s Republic of China |
title_fullStr | Clinicopathological characteristics of patients with HER2-positive breast cancer and the efficacy of trastuzumab in the People’s Republic of China |
title_full_unstemmed | Clinicopathological characteristics of patients with HER2-positive breast cancer and the efficacy of trastuzumab in the People’s Republic of China |
title_short | Clinicopathological characteristics of patients with HER2-positive breast cancer and the efficacy of trastuzumab in the People’s Republic of China |
title_sort | clinicopathological characteristics of patients with her2-positive breast cancer and the efficacy of trastuzumab in the people’s republic of china |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4846044/ https://www.ncbi.nlm.nih.gov/pubmed/27143924 http://dx.doi.org/10.2147/OTT.S97583 |
work_keys_str_mv | AT zhouping clinicopathologicalcharacteristicsofpatientswithher2positivebreastcancerandtheefficacyoftrastuzumabinthepeoplesrepublicofchina AT jiangyizhou clinicopathologicalcharacteristicsofpatientswithher2positivebreastcancerandtheefficacyoftrastuzumabinthepeoplesrepublicofchina AT huxin clinicopathologicalcharacteristicsofpatientswithher2positivebreastcancerandtheefficacyoftrastuzumabinthepeoplesrepublicofchina AT sunwei clinicopathologicalcharacteristicsofpatientswithher2positivebreastcancerandtheefficacyoftrastuzumabinthepeoplesrepublicofchina AT liuyirong clinicopathologicalcharacteristicsofpatientswithher2positivebreastcancerandtheefficacyoftrastuzumabinthepeoplesrepublicofchina AT liufang clinicopathologicalcharacteristicsofpatientswithher2positivebreastcancerandtheefficacyoftrastuzumabinthepeoplesrepublicofchina AT luorongcheng clinicopathologicalcharacteristicsofpatientswithher2positivebreastcancerandtheefficacyoftrastuzumabinthepeoplesrepublicofchina AT shaozhiming clinicopathologicalcharacteristicsofpatientswithher2positivebreastcancerandtheefficacyoftrastuzumabinthepeoplesrepublicofchina |